Raltitrexed (Tomudex™) concomitant with radiotherapy as adjuvant treatment for patients with rectal cancer:: Preliminary results of phase I studies

被引:14
作者
James, R
Price, P
Valentini, V
机构
[1] Christie Hosp, Dept Clin Oncol, Manchester M20 1BX, Lancs, England
[2] Hammersmith Hosp, Dept Clin Oncol, London W12 0HS, England
[3] Univ Cattolica Sacro Cuore, Policlin A Gemelli, Dept Radiat Therapy, Rome, Italy
关键词
raltitrexed; rectal cancer; adjuvant; chemotherapy; radiotherapy;
D O I
10.1016/S0959-8049(99)00044-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Radiotherapy, either alone or in combination with chemotherapy, may reduce local recurrence of rectal cancer following surgery and improve survival of patients with operable and advanced/recurrent/inoperable disease. Chemotherapy with 5-fluorouracil in combination with radiotherapy has been used both before and after surgery; however, the optimum schedule is unclear. In addition, alternative chemotherapy with raltitrexed (Tomudex(TM)) may be more convenient and better tolerated. The preliminary results of three phase I dose-finding studies are described, combining escalating doses of raltitrexed with radiotherapy as pre- or postoperative treatment for operable rectal cancer or as treatment for advanced/inoperable/recurrent rectal cancer. The recommended dose of raltitrexed when combined with adjuvant radiotherapy is likely to be 2.6 mg/m(2). This is a small dose reduction compared with the dose of raltitrexed for the treatment of advanced colorectal cancer (3.0 mg/m(2)); however, toxicity appears to be lower using the pre-operative approach. Neo-adjuvant therapy with raltitrexed plus radiotherapy also demonstrated clinical activity in the pre-operative study, which showed that 22% of patients achieved a complete response and 56% a partial response. Once the recommended dose has been defined in each setting, large-scale studies will be undertaken as appropriate. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:S19 / S22
页数:4
相关论文
共 15 条
[1]   THE CURRENT ROLE OF RADIOTHERAPY IN COLORECTAL-CANCER [J].
ALEMAN, BMP ;
BARTELINK, H ;
GUNDERSON, LL .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (7-8) :1333-1339
[2]  
*AM CANC SOC, 1998, FACTS FIG
[3]  
Botwood N, 1998, ANN ONCOL, V9, P38
[4]  
CIONINI L, 1996, RADIOTHER ONCOL S1, V40, P12
[5]   'Tomudex' (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia [J].
Cunningham, D ;
Zalcberg, JR ;
Rath, U ;
Olver, I ;
VanCutsem, E ;
Svensson, C ;
Seitz, JF ;
Harper, P ;
Kerr, D ;
PerezManga, G ;
Azab, M ;
Seymour, L ;
Lowery, K ;
Ackland, SP ;
Basser, RL ;
Clarke, SJ ;
Goldstein, D ;
Green, MD ;
Grygiel, JJ ;
McKendrick, JJ ;
Millward, MJ ;
Olver, IN ;
Tattersall, MHN ;
Thomson, DB ;
Jakesz, R ;
Buset, M ;
Tueni, EA ;
VanCutsem, EJD ;
Bauer, J ;
Beska, F ;
Adenis, A ;
Brunet, R ;
Francois, E ;
Paillot, B ;
Rougier, P ;
Fink, UFW ;
Knuth, KRA ;
Koenig, HJ ;
Bohme, MWJ ;
Wander, HE ;
Amadori, D ;
Frassineti, L ;
Cocconi, G ;
Passalacqua, R ;
Frigerio, F ;
Barni, S ;
Luporini, G ;
Labianca, R ;
Marini, G ;
Zaniboni, A .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (12) :1945-1954
[6]   Mature results from three large controlled studies with raltitrexed ('Tomudex') [J].
Cunningham, D .
BRITISH JOURNAL OF CANCER, 1998, 77 (Suppl 2) :15-21
[7]  
James RD, 1998, ANN ONCOL, V9, P41
[8]   STATUS OF ADJUVANT THERAPY FOR COLORECTAL-CANCER [J].
MAYER, RJ ;
OCONNELL, MJ ;
TEPPER, JE ;
WOLMARK, N .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (18) :1359-1364
[9]   COMBINED MODALITY THERAPY OF RECTAL-CANCER - DECREASED ACUTE TOXICITY WITH THE PREOPERATIVE APPROACH [J].
MINSKY, BD ;
COHEN, AM ;
KEMENY, N ;
ENKER, WE ;
KELSEN, DP ;
REICHMAN, B ;
SALTZ, L ;
SIGURDSON, ER ;
FRANKEL, J .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (08) :1218-1224
[10]  
Pahlman L, 1997, NEW ENGL J MED, V336, P980